Literature DB >> 1312369

The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria.

M Ploug1, T Plesner, E Rønne, V Ellis, G Høyer-Hansen, N E Hansen, K Danø.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal defect in bone marrow-derived cells and is clinically associated with intravascular hemolysis, hemoglobinuria, and an increased frequency of venous thrombosis. The common denominator of PNH-affected blood cells appears to be a defect in the membrane attachment of proteins normally anchored by glycosyl-phosphatidylinositol (GPI). We report here that the cellular receptor for urokinase-type plasminogen activator (u-PAR) is deficient on affected peripheral blood monocytes and granulocytes from four individuals with PNH as evidenced by chemical cross-linking analysis as well as by immunofluorescence flow cytometry using a monoclonal anti-u-PAR antibody. In contrast, on normal blood monocytes and granulocytes we find significant amounts of u-PAR, which is attached to the plasma membrane by a GPI-anchor as defined by its sensitivity towards a specific phospholipase treatment. By two-color flow cytometry it was shown that deficiency of u-PAR expression paralleled that of another GPI-anchored protein. As u-PAR is involved in the initiation of pericellular proteolysis, the reduced expression of u-PAR on PNH-affected leukocytes led to an overall reduction in the capacity for plasminogen activation by cell-surface-bound urokinase. Whereas the abnormal susceptibility of PNH-affected erythrocytes to lysis by autologous complement has been related to the low expression of three GPI-anchored complement regulatory proteins on the cell surface, we now propose that lack of u-PAR expression on the surface of peripheral blood leukocytes may be causally related to the high incidence of venous thrombosis observed in PNH patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312369

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.

Authors:  T H Bugge; M J Flick; M J Danton; C C Daugherty; J Romer; K Dano; P Carmeliet; D Collen; J L Degen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

2.  Isolated central retinal artery occlusion as an initial presentation of paroxysmal nocturnal hemoglobinuria and successful long-term prevention of systemic thrombosis with eculizumab.

Authors:  Hyun Seung Yang; So Hyun Park; Jung Ran Choi; June-Gone Kim
Journal:  Jpn J Ophthalmol       Date:  2013-06-14       Impact factor: 2.447

Review 3.  Membrane defence against complement lysis: the structure and biological properties of CD59.

Authors:  A Davies; P J Lachmann
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 4.  Thrombotic complications in paroxysmal nocturnal haemoglobinuria: a literature review.

Authors:  Alessandra Malato; Giorgia Saccullo; Lucio Lo Coco; Salvatrice Mancuso; Marco Santoro; Samuela Martino; Valentina Zammit; Delia Sprini; Sergio Siragusa
Journal:  Blood Transfus       Date:  2012-06-28       Impact factor: 3.443

Review 5.  Clinical manifestations of paroxysmal nocturnal hemoglobinuria: present state and future problems.

Authors:  Wendell F Rosse; Junichi Nishimura
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

6.  Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression.

Authors:  N K Rao; G P Shi; H A Chapman
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 7.  Paroxysmal nocturnal hemoglobinuria and the glycosylphosphatidylinositol anchor.

Authors:  E T Yeh; W F Rosse
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

8.  Microvascular thrombosis in the hepatic vein of a patient with paroxysmal nocturnal hemoglobinuria.

Authors:  Hideyoshi Noji; Tsutomu Shichishima; Masatoshi Okamoto; Akiko Shichishima-Nakamura; Hayato Matsumoto; Hiroko Tajima; Kazuei Ogawa; Yukio Maruyama
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

9.  Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

Authors:  Dominique Helley; Régis Peffault de Latour; Raphaël Porcher; Celso Arrais Rodrigues; Isabelle Galy-Fauroux; Jeanne Matheron; Arnaud Duval; Jean-François Schved; Anne-Marie Fischer; Gérard Socié
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941

10.  The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab.

Authors:  Richard Kelly; Stephen Richards; Peter Hillmen; Anita Hill
Journal:  Ther Clin Risk Manag       Date:  2009       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.